Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine and Gemcitabine in Advanced Biliary Tract Cancer
NCT00073905Phase 2Completed
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Apr 2003
- Primary completion
- Jun 2006
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine and gemcitabine in biliary tract cancer (BTC), sponsored by Swiss Group for Clinical Cancer Research. Primary endpoint: Clinical Benefit Response at 3 months. Started Apr 2003; status: completed.
02
Drugs
capecitabinegemcitabine
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT00073905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00073905.